A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors

Overview of attention for article published in Breast Cancer Research, November 2013

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (81st percentile)
Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

twitter: 7 X users
patent: 1 patent

facebook: 1 Facebook page

Citations

dimensions_citation: 86 Dimensions

Readers on

mendeley: 101 Mendeley

Summary X Patents Facebook Dimensions citations

So far, Altmetric has seen 1 public wall post.

Metastatic Breast cancer News, 20 Nov 2013

IntroductionTrastuzumab is effective in human epidermal growth factor receptor 2 (HER2)-over-expressing breast and gastric…

This page shows the most recent Facebook posts that mention this research output.

Click here to find out how to access more activity.